The Tuberous Sclerosis Alliance (TS Alliance) endeavors to stimulate, support and coordinate research that will lead to a cure for tuberous sclerosis complex (TSC), while improving the lives of those affected. A recent white paper describes the impressive scientific progress in the field and highlights key TSC research needs for the future.
The TS Alliance has funded more than $17.4 million in research on TSC since 1984. The TS Alliance Grants Program funds research focused on TSC with priorities set by the researchers together with the TS Alliance. Collaborations between basic and clinical researchers are encouraged and fostered, and the TS Alliance works constantly to increase funding for research on TSC. Download an analysis of the impact of the TS Alliance Grants Program from 1984-2010 demonstrating that principal investigators who received a total of $8.7 million from the TS Alliance garnered an additional $60 million from the NIH for TSC-related research and $6.9 million from the Department of Defense’s Congressionally Directed Medical Research Program.
The purpose of this joint request for proposals between the TS Alliance and the Rothberg Institute for Childhood Diseases is to identify and fund research opportunities that will directly enable or lead to a clinical trial for a new approach to treat TSC manifestations resulting from abnormal cell growth. These manifestations include lymphangioleiomyomatosis (LAM), renal angiomyolipomas, facial angiofibromas or other skin growths, and subependymal giant cell astrocytomas (SEGA). Successful proposals will be those that involve collaboration between researchers at the same or different institutions with the expertise and passion to address one or more of the following:
- Generate preclinical data testing the ability of a biomarker to better or more rapidly measure treatment effect that will enable more robust and efficient clinical studies,
- Develop an animal or cellular model that is superior to existing preclinical models for increasing confidence that potential treatments are likely to be effective in humans and determining the dose and duration of treatment required for testing in humans,
- Test hypotheses regarding mechanisms affecting tumor growth specific to TSC, e.g., understanding why LAM occurs primarily in women or learning why cardiac rhabdomyomas often regress at a young age, or
- Identify an existing non-rapalog molecule (or combination of molecules) that has been previously safely administered to humans, or a new non-drug intervention, that eliminates TSC-related tumors in preclinical models rather than only shrinking or stabilizing tumor growth.
- The deadline for submission of proposals for this program has passed.
- Award amount: up to $66,000 total costs per year for up to two years.
The TS Alliance Research Grants Program supports basic research by postdoctoral scientists and studies that accelerate the translation of basic research findings into improvements in quality of life for those affected by TSC. Successful proposals will be those that address one or more of the following:
- Developing future TSC researchers and clinician scientists through postdoctoral fellowships,
- Development of biomarkers to enable more robust and efficient clinical studies,
- Methods of eliminating tumors rather than only shrinking or stabilizing tumor growth, or
- Neurological, cognitive, or behavioral manifestations of TSC.
The TS Alliance anticipates releasing the next request for Letters of Intent for the Research Grant Program in spring of 2014.
For Related Inquiries, Contact:
Steve Roberds, PhD
Chief Scientific Officer
Tuberous Sclerosis Alliance
801 Roeder Road, Suite 750
Silver Spring, MD 20910
Telephone: 1-800-225-6872 or 301-562-9890 ext. 225